Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at the Boston Convention and Exhibition Center in Boston, MA.

Date: Thursday, October 12, 2023
Time: 12:15 - 1:30 PM ET
Abstract Number: 923
Poster Title: “EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study”
Session Title: Virology: Treatment and Prevention of Viral Infections
Location: Boston Convention and Exhibition Center Poster Hall
Presenter: Rachel Levene, Ph.D.

Further information about IDWeek 2023 can be found here.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^®.

Media and Investors Contact
Jennifer Viera
617-744-3848
jviera@enanta.com